Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis.

Clinical genitourinary cancer - 1 Aug 2026

Hatayama Tomoya, Sekino Yohei, Kobayashi Go, Yukihiro Kazuma, Shikuma Hiroyuki, Tasaka Ryo, Kohada Yuki, Takemoto Kenshiro, Naito Miki, Miyamoto Shunsuke, Kobatake Kohei, Kitano Hiroyuki, Goto Keisuke, Goriki Akihiro, Hieda Keisuke, Hinata Nobuyuki

Abstract excerpt

INTRODUCTION: Tumor mutational burden (TMB) is a clinically relevant biomarker for predicting responsiveness to immune checkpoint inhibitors (ICIs). However, in prostate cancer (PCa), the mechanisms underlying TMB elevation and its prognostic utility across diverse treatment regimens remain poorly understood. This study aimed to investigate the associations between TMB and clinicopathological, genomic, treatment,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ARID1A gene

Share to Mutation

Share to Neoplasm Grading

Share to Prognosis

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 42150923
DOI: 10.1016/j.clgc.2026.102568

Genes

ARID1A
SPEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis.PMID 42150923Read ↗

Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.Semantic proximity Read ↗

Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.Semantic proximity Read ↗

Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.Semantic proximity Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational BurdenSemantic proximity Read ↗

The mutational landscape of prostate cancer.Semantic proximity Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic ImplicationsSemantic proximity Read ↗

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.Semantic proximity Read ↗

Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.